Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04779697 · ClinicalTrials.gov registry record · Phase 1
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT04779697 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 96 participants.
The verdict
NCT04779697, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Interventions
- OTHER Placebo
- DRUG GLP-1 analogue - semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2024-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04779697
The ClinicalTrials.gov registry entry for NCT04779697 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04779697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04779697 about?
NCT04779697 is a clinical study titled "GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight". To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
What is the current status of trial NCT04779697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2021-02-01. Estimated completion is 2024-11-19.
What interventions are being tested in trial NCT04779697?
The interventions under investigation include: Placebo (OTHER), GLP-1 analogue - semaglutide (DRUG).
Who is sponsoring clinical trial NCT04779697?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.